26,300 Shares in Danaher Corporation $DHR Bought by Pragma Gestao DE Patrimonio Ltd.

Pragma Gestao DE Patrimonio Ltd. purchased a new stake in Danaher Corporation (NYSE:DHRFree Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 26,300 shares of the conglomerate’s stock, valued at approximately $5,195,000. Danaher makes up about 2.3% of Pragma Gestao DE Patrimonio Ltd.’s investment portfolio, making the stock its 16th biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in DHR. Red Tortoise LLC lifted its position in shares of Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after acquiring an additional 98 shares during the period. Ramirez Asset Management Inc. acquired a new stake in shares of Danaher in the 2nd quarter worth approximately $40,000. Costello Asset Management INC purchased a new position in Danaher in the 1st quarter valued at approximately $41,000. Twin Peaks Wealth Advisors LLC acquired a new position in Danaher during the second quarter worth $51,000. Finally, Strengthening Families & Communities LLC boosted its position in Danaher by 81.4% during the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after purchasing an additional 114 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $226.82 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The firm has a market cap of $160.21 billion, a PE ratio of 46.77, a P/E/G ratio of 4.35 and a beta of 0.89. The firm has a 50 day simple moving average of $213.63 and a 200-day simple moving average of $203.77. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23.

Danaher (NYSE:DHRGet Free Report) last announced its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. Danaher’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.71 earnings per share. On average, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is currently 26.39%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DHR. HSBC raised their price target on Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Monday. Barclays raised their target price on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Cowen reaffirmed a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Robert W. Baird set a $247.00 price objective on shares of Danaher in a research note on Wednesday, October 22nd. Finally, Bank of America cut their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Twenty equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $245.75.

Check Out Our Latest Stock Report on DHR

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 in the last three months. Company insiders own 11.20% of the company’s stock.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.